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Abstract
Several recent studies have reported that women who have used hormone replacement
therapy (HRT), and developed breast cancer, tend to have a better prognosis than women with
breast cancer who have not used HRT. One possible explanation is that tumors caused by HRT are
more benign than tumors caused by other factors. Although it is relevant to quantify differences in
prognostic factors across subtypes of breast cancer, it is not obvious how to do this correctly. This
is because the tumors which occur among women who are treated with HRT are a mixture of
HRT-induced and other tumors. We propose a framework based on principal stratification to
distinguish women with HRT-induced tumors from women with tumors caused by other factors.
To estimate the difference in prognosis for these two groups, we propose two estimation methods,
which can be used under both cohort and case-control sampling schemes.
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1 Introduction
It has been established that long term use of Hormone Replacement Therapy
(HRT) is a risk factor for breast cancer (Collaborative Group on Hormonal
Factors in Breast Cancer, 1997). There is also clear evidence of a dosage effect
of HRT on risk (See Figure 3 in Million Women Study Collaborators (2003)).
Many recent studies have investigated the relationship between HRT use and
prognosis in breast cancer patients; see Antoine et al (2004) for an overview.
Most of these studies reported HRT to be associated with a favorable progno-
sis. Several authors have suggested that this association may be explained by
confounding due to non-randomization of HRT. Taken at face value however
the association has a plausible explanation; that HRT is associated with an
increased risk of tumors which are less aggressive than other breast cancer
tumors. This explanation has been suggested by, for example, Rosenberg et
al (2008) in their interpretation of a case-only regression analysis of prognosis
on HRT. This argument implies unobserved heterogeneity of breast cancers, in
terms of prognosis. A case-only regression analysis of prognosis on HRT, treat-
ing all cancers as a homogeneous group, can therefore be considered inappro-
priate for assessing the HRT-prognosis relationship. We propose an alternative
analysis approach which explicitly accounts for this heterogeneity. To see how
HRT being associated with an increased risk of less aggressive tumors can
lead to its opposite relationships with risk and prognosis, consider a simplified
scenario in which each women is classified as either ‘treated’ (with HRT) or
‘untreated’ (We will later consider HRT on a continuous scale). Suppose that
there exists three types of women; 1) those who do not develop cancer regard-
less of whether they are treated with HRT or not - we may call them ‘healthy’,
2) those who develop cancer if they are treated, but not otherwise - we may
call them ‘sensitive’, and 3) those who develop cancer regardless of whether
they are treated or not - we may call them ‘doomed’. Table 1 illustrates this
classification. We may interpret ‘sensitive’ (under treatment) and ‘doomed’ as
subject type
cancer healthy sensitive doomed
HRT
no no no yes
yes no yes yes
Table 1: Classification of women into ‘healthy’, ‘sensitive’, and ‘doomed’.
carriers of biologically different tumor types. ‘Sensitive’ individuals develop
1
Sjolander et al.: A Principal Stratification Approach
Brought to you by | Universiteit Gent (Universiteit Gent)
Authenticated | 172.16.1.226
Download Date | 6/11/12 4:33 PM
tumors (under treatment) which are caused by HRT, whereas ‘doomed’ indi-
viduals have tumors of other causes. In realistic studies, these types of women
can not be uniquely distinguished. Women who develop breast cancer that
have not been treated with HRT must be ‘doomed’, whereas those who are
treated and develop cancer are a mixture of ‘sensitive” and ‘doomed’. By as-
sessing the association between HRT and prognosis in breast cancer patients,
we are comparing the prognosis for untreated women with tumors not caused
by HRT (‘doomed’) against a mixture of treated women with tumors caused
by HRT (‘sensitive’) and tumors not caused by HRT (‘doomed’). If women
with tumors caused by HRT have a better prognosis than women with tumors
not caused by HRT (Table 2), then it is clear that the treated patients will
have a favorable prognosis compared to untreated patients. According to our
discussions with subject matter experts if a woman’s tumor has not been (clin-
ically) induced by hormones then it is not likely that the amount of hormones
she has been exposed to will influence her prognosis. Table 2 is, however, not
the only possible explanation of HRT having opposite risk/prognosis relation-
ships. Such relationships would also manifest if HRT improves the prognosis
for those who have tumors not caused by HRT (Table 3). Another possibility
leading to the same HRT-risk/prognosis relationships is that prognosis is HRT
dependent within the doomed stratum, with the HRT group having a worse
prognosis than the no HRT group among the doomed, but that the sensitive
stratum has the most favorable prognosis. Given however that Table 2 is the
most plausible and has been implied by breast cancer researchers, it is of clini-
cal interest to quantify the association between HRT and prognosis under this
condition, which is what we do in this article. To do this, however, is not a
trivial task since women with different tumor subtypes can not be uniquely
distinguished.
subject type
prognosis healthy sensitive doomed
HRT
no * * unfavorable
yes * favorable unfavorable
Table 2: Illustration of the hypothesis that women with tumors caused by
HRT have a better prognosis than women with tumors not caused by HRT.
In this paper we formalize the relationship between HRT use and prognosis
along the lines outlined above, using the framework of potential outcomes and
principal stratification (Frangakis and Rubin, 2002). We consider a general
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subject type
prognosis healthy sensitive doomed
HRT
no * * unfavorable
yes * favorable favorable
Table 3: Illustration of the hypothesis that HRT improves the prognosis for
those who have tumors not caused by HRT.
scenario, for which HRT is defined on a continuous scale, and for which ad-
ditional information on covariates is available. We show that under a set of
reasonable assumptions, we can estimate the difference in prognosis for women
with tumors caused by HRT, and women with tumors caused by other factors.
The paper is organized as follows. In Section 2 we show how the framework
of potential outcomes and principal stratification can be applied within the
context of HRT, breast cancer, and prognosis. We lay out a number of fun-
damental assumptions and define the estimand of interest, which is a measure
of the difference in prognosis for women with different tumor subtypes. In
Sections 3 and 4 we discuss identifiability of the estimand, and propose two
estimation methods. We consider both inference for cohort studies (Section 3)
and for case-control studies (Section 4). In Section 5 we apply the proposed
method to data from a population based case-control study of postmenopausal
breast cancer in Swedish women. In Section 6 we carry out a small simulation
study to investigate the performance of our approach. In Section 7 we discuss
how our work relates to the literature on post-treatment selection bias.
2 Definitions and assumptions
We use Z to denote disease status; Z = 1 for cancer and Z = 0 for no cancer.
We useX to denote duration of past HRT use. We assume thatX is continuous
on the range [0,∞), where ‘0’ corresponds to ‘no past HRT use’. We use C
to denote measured baseline covariates. C is allowed to contain covariates
measured on any mixture of scales. We assume that for each woman diagnosed
with cancer, a particular prognostic factor Y is measured. Y is allowed to be
measured on any scale. We assume that higher levels of Y indicate a worse
prognosis. To define the target estimand we follow Frangakis and Rubin (2002)
and use the framework of potential outcomes and principal stratification. We
let Z(x) and Y (x) denote the potential outcomes of Z and Y , at HRT level
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X = x. The following consistency assumption relates the potential outcomes
to the observables:
A 1 Z(X) = Z; Y (X) = Y .
A1 states that the potential outcomes corresponding to the factual HRT level
are equal to the observed outcomes Z and Y . The potential outcomes cor-
responding to the other (counterfactual) levels are unobserved, and are con-
sidered as missing. For mathematical convenience we define Y (x) = ∗ (‘not
defined’) when Z(x) = 0 (⇒ Y = ∗ when Z = 0). Let Z(·) denote the entire
potential outcome function {Z(x) ∀x}. Figure 1 shows three examples of po-
tential outcome functions. The solid line represents women who develop cancer
if and only if they are treated with HRT for 3 or more years. The dashed line
represents women who develop cancer if and only if they are treated with HRT
for less than 4 years. The dotted line represents women who develop cancer if
they are treated with HRT for 1-2 years or 5-6 years. We say that two women
belong to the same principal stratum if they have the same potential outcome
functions Z(·).
Although HRT could hypothetically prevent breast cancer for some women,
this is unlikely. We therefore assume that a woman who develops cancer at
one level of HRT, would also have developed cancer if she would have been
exposed to a higher level of HRT:
A 2 Z(x) ≥ Z(x′) if x ≥ x′.
Under A2, Z(·) is a step function such as the solid line in Figure 1, and
functions such as the dashed and dotted line are assumed not to exist. Hence,
under A2, we can, without loss of information, summarize Z(·) into a scalar,
R, defined as the minimum level x for which Z(x) = 1. For a woman with
Z(·) represented by the solid line in Figure 1, R = 3. R is continuous on the
range (0,∞), and its distribution has a point mass at 0, where the stratum
whose women develop cancer regardless of whether they are treated or not
(Z(x) = 1 ∀x), is represented. Previous research has established a dose-
respone relationship in line with A2 (Million Women Study Collaborators,
2003). Furthermore, all subject matter experts that we have discussed the
issue with, have confirmed that A2 is reasonable from a biological perspective.
We will assume that X can be considered randomized within levels of C.
In terms of potential outcomes we formulate this assumption as
A 3 {Y (x), R} qX|C ∀x,
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Figure 1: Examples of potential outcome functions.
where q is used to denote statistical independency. We remind the reader that
Y (x) = ∗ when x < R. Whether A3 is plausible or not depends, of course,
on which covariates are included in C. Women use HRT for several reasons,
but mainly because of menopausal symptoms, to prevent osteoperosis or to
prevent heart disease. Thus, relevant covariates, which we have used in our
analysis of data (Section 5), are age and BMI. If all relevant covariates are
included in C, A3 follows naturally.
For our purpose it is useful to think about the principal strata as represent-
ing women with different types of cancers. We distinguish between two types
of cancers, those which are HRT-induced and those which are not. We call a
specific tumor HRT-induced if it occurs in the presence of HRT use, but would
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not have occurred in the absence of HRT use. A woman with R > 0 who devel-
ops cancer (Z = 1), would not have done so had she not been treated. Thus,
for a woman with (R > 0, Z = 1), the cancer is HRT-induced. A woman with
R = 0 develops cancer regardless of whether she is treated or not. If she is not
treated, then we can with certainty say that the cancer is non-HRT-induced.
If she is treated, then the situation is more complex. Hypothetically, she may
develop two types of cancer under HRT use, one which is HRT-induced and
one which is non-HRT-induced. In this case, the observed cancer may be either
exactly one of these types (if one of them occurred and was diagnosed before
the other one occurred), or a combination of both. For most women, however,
(moderate levels of) HRT does not cause cancer. Hence, most of the observed
cancers within R = 0 are bound to be non-HRT-induced. We therefore proceed
by assuming that women with cancer and R > 0 have HRT-induced tumors,
and women with cancer and R = 0 have non-HRT-induced tumors. We note
that this assumption is crucial in our analysis as it entails identification by
eliminating the ‘competing risk problem’ with one tumor type preempting the
other.
By contrasting the distribution of potential outcomes Y (x) for the stratum
0 < R ≤ x with the stratum R = 0, we measure the discrepancy in prognosis
between women with HRT-induced tumors vs women with non-HRT-induced
tumors. More specifically, our target estimand is
m(x,C) ≡ g[E{Y (x)|0 < R ≤ x,C}]− g[E{Y (x)|R = 0, C}], x > 0,
where g(·) is a known, smooth, monotone link function. We definem(0, C) ≡ 0.
We note that m(x,C) does not measure the causal effect of HRT on prognosis
per se. This is because it compares the potential outcome Y (x) for two different
groups of people (Frangakis and Rubin, 2002). In particular, suppose that
there exists a mutation in a gene which causes non-HRT-induced tumors and
also affects general health status through other pathways. In such case, women
with HRT-induced tumors and women with non-HRT-induced tumors will have
different prognosis (m(x,C) 6= 0), even if the tumors themselves are completely
identical in every relevant aspect. To separate such a ‘confounding effect’ from
a ‘tumor effect’, however, would require randomization of tumors, which is, of
course, not possible.
To better understand what m(x,C) does measure, consider the following
simple numerical example. Assume that X is categorical with levels {0, 1, 2},
and that the population can be divided into three principal strata R = 0, R =
1, and R = 2, with equal population proportions, given covariates C; Pr(R =
r|C) = 1/3 for r ∈ {0, 1, 2}. Women with R = 0 develop cancer regardless
of treatment level. These cancers are non-HRT-induced. Women with R = 1
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develop cancer if they are treated at level X = 1 or X = 2, and women with
R = 2 develop cancer only if they are treated at level X = 2. These cancers
are HRT-induced. Assume that E{Y (x)|R = 0, C} = 3 for x ∈ {0, 1, 2},
E{Y (x)|R = 1, C} = 2 for x ∈ {1, 2}, and E{Y (2)|R = 2, C} = 0. The
situation is represented in Table 4. m(1, C) compares the mean prognosis for
R
E{Y (x)|R,C} 2 1 0
0 * * 3
x 1 * 2 3
2 0 2 3
Table 4: Numerical example 1. Y (x) ≡ ∗ when R > x⇔ Z(x) = 0.
women with HRT-induced tumors vs women with non-HRT-induced tumors,
at treatment level X = 1. Assuming an identity link, g(·) = ·, we have
that m(1, C) = E{Y (1)|R = 1, C} − E{Y (1)|R = 0, C} = 2 − 3 = −1.
m(2, C) compares the mean prognosis for women with HRT-induced tumors
vs women with non-HRT-induced tumors, at treatment level X = 2. We
have that m(2, C) = E{Y (2)|R = 2, C} Pr(R=2|C)
Pr(R=2|C)+Pr(R=1|C) + E{Y (2)|R =
1, C} Pr(R=1|C)
Pr(R=2|C)+Pr(R=1|C) − E{Y (2)|R = 0, C} = 0 × 1/31/3+1/3 + 2 × 1/31/3+1/3 −
3 = −2. In this numerical example, women with HRT-induced tumors have
different a prognosis than women with non-HRT-induced tumors, at both levels
X = 1 and X = 2, since neither m(1, C), nor m(2, C) equals 0. Furthermore,
this difference becomes more accentuated at higher levels of HRT use, since
m(2, C) < m(1, C).
The example further clarifies that m(x,C) is not a measure of the HRT
effect on prognosis per se. Indeed, within each stratum R, the mean prognosis
is the same for all HRT-levels at which Z(x) = 1. Hence, although m(x,C)
depends on treatment level in this example, HRT does not have any effect on
prognosis. The reason why m(x,C) depends on treatment level in the example,
is because women with HRT-induced tumors occurring at level X = 2 have
different prognosis from women with HRT-induced tumors occurring at level
X = 1. That m(x,C) is not a measure of the HRT effect per se, however,
does not mean that it is not influenced by an existing HRT effect. To see
this, consider the numerical example in Table 5. In this second example,
m(1, C) = −1 and m(2, C) = −2, as in the first example, but HRT now has
an effect on prognosis for women within R = 1, since E{Y (2)|R = 1, C} 6=
E{Y (1)|R = 1, C}. The two examples tell us that an x-gradient in m(x,C)
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R
E{Y (x)|R,C} 2 1 0
0 * * 3
x 1 * 2 3
2 1 1 3
Table 5: Numerical example 2. Y (x) ≡ ∗ when R > x⇔ Z(x) = 0.
may be explained either by heterogeneity in prognosis for women with HRT-
induced tumors, or by an HRT effect on prognosis, or a combination of both.
To disentangle one phenomenon from the other would require additional strong
assumptions.
If a particular woman has a tumor which is HRT-induced, then it is quite
possible that her prognosis depends on the dosage of HRT. A larger dosage
may for example cause a more aggressive cancer. According to our discussions
with subject matter experts, if a woman’s tumor is non-HRT-induced, then
there is no reason to believe that her prognosis is affected by her dosage of
HRT. In particular we will assume
A 4 Pr{Y (x)|R = 0, C} = Pr{Y (0)|R = 0, C} ∀x.
3 Inference from cohort studies
A cohort study generates an iid sample from Pr(Y, Z,X,C).
3.1 Identification
Define pi(X,C) ≡ Pr(Z = 1|X,C). Under A1-A3 it can be shown (see Ap-
pendix A) that
Pr(R ≤ x|C) = pi(x,C) (1)
In particular we have that Pr(R = 0|C) = pi(0, C). The relation in (1)
implies that under cohort sampling, the conditional distribution of principal
strata, Pr(R|C), is identified. Equation (1) also implies the following testable
restriction
pi(x,C) ≥ pi(x′, C) if x ≥ x′. (2)
Thus, under cohort sampling, A1-A3 are partially testable, since violations of
the inequality in (2) falsify at least one of the assumptions.
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Under A1-A3 the conditional distribution of Y , given (Z = 1, X, C), is a
mixture of potential outcomes for women with HRT-induced and non-HRT-
induced cancers (see Appendix A):
Pr(Y |Z = 1, X = x,C)
= Pr{Y (x)|R = 0, C}pi(0, C)
pi(x,C)
+ Pr{Y (x)|0 < R ≤ x,C}
{
1− pi(0, C)
pi(x,C)
}
.
(3)
The key to identifiability of the mixture components is A4. Combining (3)
with A4 gives that
m(x,C)
= g
{
E(Y |Z = 1, X = x,C)− E(Y |Z = 1, X = 0, C) pi(0,C)
pi(x,C)
1− pi(0,C)
pi(x,C)
}
− g{E(Y |Z = 1, X = 0, C)}.
(4)
The expression in (4) shows that m(x,C) is identified if pi(x,C) 6= pi(0, C).
We will throughout assume that this is the case.
In order for Pr{Y (x)|0 < R ≤ x,C} to be a proper density/distribution, it
has to be non-negative. This requirement, combined with (3) and A4, shows
that A4 implies the following additional testable restriction
Pr(Y, Z = 1|X = 0, C) ≤ Pr(Y, Z = 1|X,C). (5)
It can be shown (see Appendix B) that A1-A4 do not imply any restrictions
on the joint distribution for (Y, Z,X,C) other than those stated by (2) and
(5). We note that although A1-A4 imply (2) and (5), the reverse does not
hold. Thus, A1-A4 can be faslified but not verified from data.
3.2 Estimation
Modeling of m(x,C) is required to deal with its high dimensionality. We
propose two approaches; one implicit (Section 3.2.1) and one explicit (Section
3.2.2).
3.2.1 Implicit method
One possible approach is to specify models for E(Y |Z = 1, X, C) and pi(X,C)
indexed by ξ and α, respectively, and use the relation in (4) to translate these
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models into a model for m(x,C). For example, using the standard models
E(Y |Z = 1, X, C; ξ) = ξ0 + ξ1X + ξ2C (6)
logitpi(X,C;α) = α0 + α1X + α2C, (7)
and the identity link g(·) = ·, yields
m(x,C; ξ, α) =
ξ1x
1− expit(α0+α2C)expit(α0+α1x+α2C)
. (8)
One can view the denominator in (8) as a ‘bias correction’, required to give the
regression parameter ξ1 the desired interpretation as a difference in prognosis
between women with different tumor subtypes. Replacing ξ and α with their
(ML-)estimates, ξˆ and αˆ, yields an estimate of m(x,C; ξ, α). The standard
error of m(x,C; ξˆ, αˆ), as a function of (x,C), can be obtained from the delta
method. We will refer to this method as ‘implicit’. The advantage of the
implicit method is that it is computationally straightforward. A disadvantage
is that the implied model for m(x,C) may be quite complex and hard to inter-
pret. In general, m(x,C; ξ, α) depends on x through the full parameter vector
(ξ, α), and through the particular value of the covariate vector C. Hence,
it may be hard to formulate scientifically relevant questions about m(x,C)
using the implicit method. An important exception is the null hypothesis
m(x,C) = 0. From (4), it follows that m(x,C) = 0 ⇔ E(Y |Z = 1, X, C) =
E(Y |Z = 1, C). Hence, under (6), a test for m(x,C) = 0, ∀x, is equivalent
to a test for ξ1 = 0. The relation E(Y |Z = 1, X, C) = E(Y |Z = 1, C) can
of course be tested in other parametric or semiparametric models as well, or
even nonparametrically.
3.2.2 Explicit method
In this section we propose an alternative method in which m(x,C) is modeled
directly, and works when g(·) is the identity link or the log-link. We will refer
to this method as ‘explicit’. The explicit method involves fitting one main
model together with three ‘nuisance’ models.
Main model. We assume a model for m(x,C) indexed by a parameter ψ:
m(x,C) = m(x,C;ψ). (9)
An example is the linear model
m(x,C;ψ) = ψ0 + ψ1x. (10)
10
The International Journal of Biostatistics, Vol. 6 [2010], Iss. 1, Art. 20
DOI: 10.2202/1557-4679.1225
Brought to you by | Universiteit Gent (Universiteit Gent)
Authenticated | 172.16.1.226
Download Date | 6/11/12 4:33 PM
In (10), ψ0 = lim
x→0
m(x,C) represents an intrinsic, non-HRT-dependent, dif-
ference in prognosis between women with different tumor subtypes, whereas
1 = m(x+1, C)−m(x,C) represents a x-gradient in m(x,C). If, for example,
people with HRT induced tumors have (on average) a better prognosis than
people with non-HRT-induced tumors, but the particular level of HRT is not
associated with the prognosis, then (ψ0 6= 0, ψ1 = 0). If the level of HRT has
an influence on the prognosis, then we would expect that ψ1 6= 0 as well. Note
0 6= 0 implies a discontinuity for m(x,C) in 0, i.e.lim
x→0
m(x,C) 6= m(0, C). In
a comparison m(x + 1, C) − m(x,C) this discontinuity cancels. In (10), we
make the assumption that m(x,C) does not depend on C. This assumption
does not imply that E{Y (x)|R,C} does not depend on C. Since m(x,C) is
a mean difference, it implies that there is no interaction between x and C on
the particular scale defined by g(·). For the identity link, we define
Hi(ψ) = Yi −m(Xi, Ci;ψ)
{
1− pi(0, Ci)
pi(Xi, Ci)
}
. (11)
For the log-link, we define
Hi(ψ) =
Yi
pi(0,Ci)
pi(Xi,Ci)
+ exp{m(Xi, Ci;ψ)}
{
1− pi(0,Ci)
pi(Xi,Ci)
} . (12)
We estimate ψ as the solution to the estimating equation
n∑
i=1
d(Xi, Ci)Zi{Hi(ψ)− q(Ci)} = 0,
ψ
(13)
where d(Xi, Ci) ∈ Rp is an arbitrary function satisfying E{d(Xi, Ci)|Zi =
1, Ci} = 0, and q(Ci) is an arbitrary function. The estimating equation in (13)
is unbiased (see Appendix C) which assures that the solution, ˆ, is consistent,
and asymptotically normal (under standard regularity conditions). We define
Gi = E
{
∂Hi(ψ)
∂ψ
|Zi = 1, Xi, Ci
}
,
We will use the index functions
dopt(Xi, Ci) = σ
−2(Xi, Ci)
[
Gi − E {Giσ
−2(Xi, Ci)|Zi = 1, Ci}
E {σ−2(Xi, Ci)|Zi = 1, Ci}
]
,
where σ2(Xi, Ci) ≡ Var {Hi(ψ)|Zi = 1, Xi, Ci}, and
qopt(Ci) = E(Yi|Zi = 1, Xi = 0, Ci).
11
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ψψ
It can be shown that these index functions maximize the efficiency of ˆ (see
Appendix D). We will throughout assume homoscedasticity; σ2(Xi, Ci) = σ
2.
This assumption does not induce bias if it is violated, but at worst a loss of
efficiency. Under homoscedasticity, dopt(Xi, Ci) simplifies to
dopt(Xi, Ci) = σ
−2{Gi − E(Gi|Zi = 1, Ci)}.
When solving the equation in (13), σ2 cancels. In practice, both pi(Xi, Ci)
and the index functions dopt(Xi, Ci) and q
opt(Ci) are unknown, and must be
estimated. Estimation of these quantities is described below.
As shown in Appendix C, the estimating equation in (13) has the attractive
feature of being unbiased when either E{d(Xi, Ci)|Zi = 1, Ci} = 0, or q(Ci) =
qopt(Ci). This implies that it is doubly robust, in the sense that ˆ is consistent
as long as, in addition to the models for m(x,C) and pi(X,C), at least one of
the index functions is correctly specified. The proposed estimator is somewhat
related to doubly robust estimators found in the context of semiparametric
regrssion models (Robins and Rotnitzky, 2001). For an overview of the use of
doubly robust estimators, see Bang and Robins (2005).
Nuisance model 1. To estimate pi(Xi, Ci) we specify a model
pi(Xi, Ci) = pi(Xi, Ci;α). (14)
We obtain a consistent estimate of α by solving the maximum likelihood score
equation
n∑
i=1
Si(α) =
n∑
i=1
∂
∂α
log[pi(Xi, Ci;α)
Zi{1− pi(Xi, Ci;α)}1−Zi ] = 0. (15)
After having solved (15), we replace the true value of pi(Xi, Ci) in (13) with its
estimate, pi(Xi, Ci; αˆ). In Appendix D, we provide a more efficient estimation
strategy based on joint estimation of ψ and α.
Nuisance model 2. To estimate qopt(Ci) we specify a model
E(Yi|Zi = 1, Xi = 0, Ci) = µ(Ci; β). (16)
We obtain a consistent (and efficient) estimate of β by solving the unbiased
equation
n∑
i=1
∂µ(Ci; β)/∂β
var(Yi|Zi = 1, Xi = 0, Ci)I(Xi = 0)Zi{Yi − µ(Ci; β)} = 0, (17)
When Hi(ψ) is defined as in (11), the assumption that σ
2(Xi, Ci) = σ
2 implies
that var(Yi|Zi = 1, Xi = 0, Ci) = const. For Hi(ψ) defined as in (12), we will
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also assume that var(Yi|Zi = 1, Xi = 0, Ci) = const. After having solved (17)
we replace the true value of qopt(Ci) in (13) with its estimate, µ(Ci; βˆ).
Nuisance model 3. To estimate dopt(Xi, Ci) we need to estimate the
conditional mean E{Gi|Zi = 1, Ci}. One option is to specify an explicit model
for E{Gi|Zi = 1, Ci}. This approach has three disadvantages. 1) E{Gi|Zi =
1, Ci} is determined by the law Pr(X|Z = 1, C). This law is not variation
independent of the law pi(X,C), and as a consequence an explicit model for
E{Gi|Zi = 1, Ci} may not be logically compatible with the model pi(X,C;α).
2) Fitting the model for E{Gi|Zi = 1, Ci} requires knowing the true value of Gi
for each woman. This value, however, depends on the true value of ψ. Thus, an
estimating equation for the parameter indexing the model for E{Gi|Zi = 1, Ci}
has to be solved simultaneously with the equation for ψ, which increases the
computational complexity. 3) Gi is a complicated function of the observables,
and it may be hard, even for a subject matter expert, to well specify a model
for its conditional mean. We therefore propose an alternative approach. We
use Bayes rule to rewrite E{Gi|Zi = 1, Ci} as
E{Gi|Zi = 1, Ci} = E{Gipi(Xi, Ci)|Ci}
E{pi(Xi, Ci)|Ci} .
ψ
ψ
(18)
If we model and estimate the law Pr(Xi|Ci) we can calculate E{Gi|Zi =
1, Ci} by averaging over Gipi(Xi, Ci) and pi(Xi, Ci) conditional on Ci in (18).
Thus, an explicit model for Pr(Xi|Ci) translates into an implicit model for
E{Gi|Zi = 1, Ci}. Pr(Xi|Ci) is clearly variation independent of pi(X,C),
which rules out any model incompatibilities. Furthermore, the parameters of
the model for Pr(Xi|Ci) can be estimated without knowledge of ψ. Finally,
when X represents a treatment ordinated by a physician, a subject matter
expert may well be able to roughly specify the treatment distribution across
levels of covariates. Note also that the model for Pr(Xi|Ci) does not need to be
entirely correct in order for ˆ to be consistent so long as it yields the correct
ratio of conditional expectations in (18). Furthermore, it follows from the
double robustness of the estimating equation in (13) that ˆ will be consistent
even if this ratio is misspecified, as long as the model for E(Yi|Zi = 1, Xi =
0, Ci) in (16) is correct. We specify a model
Pr(Xi|Ci) = Pr(Xi|Ci; γ). (19)
We obtain a consistent (and efficient) estimate of γ by solving the maximum
likelihood score equation
n∑
i=1
Si(γ) =
n∑
i=1
∂
∂γ
logPr(Xi|Ci; γ) = 0. (20)
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3.2.3 Asymptotic properties of the explicit method
Define θ = (α′, β′, γ′, ψ′)′. Estimating θ following the procedure described
above is equivalent to solving the joint equation
n∑
i
Ui(θ) =

Si(α)
∂µ(Ci;β)/∂β
var(Yi|Zi=1,Xi=0,Ci)I(Xi = 0)Zi{Yi − µ(Ci; β)}
Si(γ)
dopt(Xi, Ci;α, γ)Zi{Hi(ψ, α)− qopt(Ci; β)}
 = 0,
where we have highlighted the dependency on (α, β, γ) in the last row of the
equation system. Under regularity conditions, the combined estimating equa-
tion has a unique solution θˆ, where n1/2(θˆ − θ) has an asymptotically normal
distribution with mean 0 and variance
E ′
{
∂Ui(θ)
∂θ
}−1
var{Ui(θ)}E
{
∂Ui(θ)
∂θ
}−1
(21)
Replacing θ in (21) by θˆ and the population moments by their sample coun-
terparts yields a sandwich estimator for the variance of θˆ.
4 Inference from case-control studies
A case-control study generates two samples; one iid sample of size n1 from
Pr(Y,X,C|Z = 1), and one iid sample of size n0 from Pr(X,C|Z = 0). We
define n ≡ n0+n1. We develop inference for m(x,C) assuming a low prevalence
of breast cancer, i.e.
A 5 pi(x, c) ≈ 0 ∀x, c.
This assumption is often reasonable as it forms the basis for choosing case-
control designs in practice.
4.1 Identification
Under a case-control sampling scheme, pi(X,C) is not identified. Hence,
the conditional distribution of principal strata, Pr(R|C), is not identified.
When the disease is rare (A5), this poses no major identification problems for
m(x,C). To see this, note that the expression in (4) only contains E(Y |Z =
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1, X, C), which is trivially identified under case-control sampling, and the rel-
ative risk pi(0,C)
pi(x,C)
. Define the odds ratio
η(X,C) ≡ pi(X,C){1− pi(0, C)}
pi(0, C){1− pi(X,C)} .
It is well known that when pi(X,C) ≈ 0, the relative risk pi(0,C)
pi(X,C)
approximates
the odds ratio η−1(X,C). From Bayes rule, η(X,C) is trivially identified from
case-control sampling, and equal to Pr(X|Z=1,C)Pr(X=0|Z=0,C)
Pr(X|Z=0,C)Pr(X=0|Z=1,C) . Hence, under
A1-A5, m(x,C) is ‘approximately’ identified under case-control sampling.
We note that A1-A3 are partially testable under case-control sampling,
even when A5 is violated. This is because the restriction in (2) implies the
testable odds ratio restriction
η(x,C) ≥ η(x′, C) if x ≥ x′. (22)
4.2 Estimation
Under A5, both estimation procedures for cohort studies proposed in Section
3.2 can be used for case-control studies, with the following minor modifications.
4.2.1 Modified implicit method
Under A5, the implicit estimation method described in Section 3.2.1 can easily
be adapted to case-control studies by replacing the relative risk pi(0,C)
pi(x,C)
in (4)
with the odds ratio η−1(x,C). As an example, consider the implied model in
(8). Under the rare-disease approximation, this model simplifies to
m(x,C; ξ, α) =
ξ1x
1− exp(−α1x) . (23)
Hence, under A1-A5, g(·) = ·, and the standard models in (6) and (7), m(x,C)
only depends on x through ξ1 and α1. It is instructive to consider the asymp-
totic (in x) behavior of the implied model in (23). We have that
lim
x→0
m(x,C; ξ, α) = ξ1/α1,
lim
x→∞
m(x,C; ξ, α)/x = ξ1.
The limit value of ξ1/α1 can be interpreted as an intrinsic, non-HRT-dependent,
difference in prognosis between women with different tumor subtypes, similar
to ψ0 in (10). The limit value of ξ1 reflects the fact that for large values of x
we expect that most tumors are HRT-induced. Hence, for large values of x,
m(x,C)/x ≈ {E(Y |Z = 1, X = x,C)− E(Y |Z = 1, X = 0, C)}/x = ξ1.
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4.2.2 Modified explicit method
To adapt the explicit method described in Section 3.2.2 to case-control studies,
we make the following approximations.
1. Hi(ψ) contains the relative risk
pi(0,Ci)
pi(Xi,Ci)
. We replace the relative risk
with the odds ratio, η−1(Xi, Ci), and use H˜i(ψ) to denote the resulting
approximation to Hi(ψ).
2. To calculate the efficient1 index function, dopt(Xi, Ci), we need to cal-
culate Gi and E{Gi|Zi = 1, Ci}. Gi contains the relative risk pi(0,Ci)pi(Xi,Ci) .
˜
We replace the relative risk with the odds ratio, η−1(Xi, Ci), and use
Gi to denote the resulting approximation to Gi. Fitting an implicit
model for E{Gi|Zi = 1, Ci} (see Section 3.2.2) involves fitting a model
for Pr(Xi|Ci) and averaging over Gipi(Xi, Ci) and pi(Xi, Ci), conditional
on Ci. Under case-control sampling this is not straightforward, because
neither pi(Xi, Ci), nor Pr(Xi|Ci) is identified. Under A5, however, we
have that Pr(Xi|Ci) ≈ Pr(Xi|Zi = 0, Ci). Hence, we may fit the model
for Pr(Xi|Ci) to the controls separately. We thus replace the estimating
equation in (20) by
n∑
i=1
(1− Zi)Si(γ) = 0,
which yields an approximately consistent estimate of γ under A5. We
further divide the numerator and denominator in (18) by pi(0, Ci) to
obtain
E{Gi|Zi = 1, Ci} =
E
{
Gi
pi(Xi,Ci)
pi(0,Ci)
|Ci
}
E
{
pi(Xi,Ci)
pi(0,Ci)
|Ci
} ≈ E
{
G˜iη(Xi, Ci)|Ci
}
E {η(Xi, Ci)|Ci} , (24)
where the approximation is valid under A5. We use d˜opt(Xi, Ci) to de-
note the estimate of dopt(Xi, Ci) obtained by replacing Gi by G˜i, and
E{Gi|Zi = 1, Ci} by the right-hand-side of (24).
1Note that the dopt(Xi, Ci) is efficient under cohort sampling, but may not be efficient
under case-control sampling. We conjecture though, that this is the case. This conjecture
is supported by van der Laan (2008), who showed that the efficient score under cohort
sampling stays efficient if it is inversely weighted by the known disease prevalence under
case-control sampling.
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Under A5, H˜i(ψ) ≈ Hi(ψ) and d˜opt(Xi, Ci) ≈ dopt(Xi, Ci), and the modified
estimation method gives an approximately consistent estimate of ψ. When
A5 is violated, then E{d˜opt(Xi, Ci)|Zi = 1, Ci} may differ significantly from 0.
Hence, the modified procedure may be more robust to deviations from A5 if
E{Gi|Zi = 1, Ci} is modeled explicitly. Note also, that one of the arguments
that we gave in Section 3.2.2 for not modeling E{Gi|Zi = 1, Ci} explicitly, is
invalid under case-control sampling. More specifically, when pi(Xi, Ci) is only
modeled up to the odds ratio η(Xi, Ci), then there is no risk for incompati-
bility between the models for E{Gi|Zi = 1, Ci} and η(Xi, Ci), since the law
Pr(X|Z = 1, C) is variation independent of η(Xi, Ci) (see Appendix F). To
estimate the odds ratio η(Xi, Ci) it is natural to assume that pi(Xi, Ci) follows
a logistic regression model. If so, a consistent estimate of η(Xi, Ci) is obtained
as the solution to the score equation (15) (Prentice and Pyke, 1979).
The variance expression in (21) is valid under cohort sampling. When the
study is subject to case-control sampling, the variance expression must ac-
knowledge this. Assume that nzn
−1 = ρz. Using a standard Taylor expansion
argument, it can be shown (see Appendix E) that n1/2(θˆ−θ) obtained from the
estimation procedure described in this section, has an asymptotically normal
distribution with mean 0 and variance I ′−1J I−1, where
I =
∑
z∈{0,1}
ρzE
{
∂Ui(θ)
∂θ
∣∣Z = z}
and
J =
∑
z∈{0,1}
ρzvar{Ui(θ)|Z = z}.
Replacing θ in (21) by θˆ and the population moments by their sample coun-
terparts yields a sandwich estimator for the variance of θˆ.
5 Application
We used the methods described above to analyze data from a large population-
based case-control study of breast cancer in Swedish post-menopausal women,
aged 50 to 74 years in 1993-1995. The study, known as CAHRES (Cancer
And Hormone REplacementS), compares 3000 cases, and a similar number
of healthy controls. Several papers have been published based on this data
(e.g. Magnusson (1999)). Recently, Rosenberg (2006) analyzed breast can-
cer prognosis data obtained from the Swedish death registry, for cases in this
17
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study, for association with HRT use. In line with the observational studies
reviewed by Antoine et al (2004), Rosenberg (2006) reported a positive as-
sociation between HRT use and favorable prognostic factors. In particular,
associations were found between tumor size and grade. For our analysis we
have combined these two prognostic factors into a single prognostic index (PI):
PI = log{size(cm) + grade(1-3)}. A small value is interpreted as carrying a
favorable prognosis. Equal weights for size and grade are used, as is also the
case in the Nottingham Prognostic Index (NPI; Galea et al (1992)), a breast
cancer prognosis index developed in the 1990’s. Due to missingness in size
and/or grade, PI could only be calculated for 986 cases. In what follows we
use Y to denote the PI and X to denote duration of HRT use (in 1000 days
using estrogen or progestin). We include age and body mass index (BMI) in
the covariate vector C.
Before carrying out an analysis using the methods described in this paper,
we assessed the appropriateness of the underlying assumptions 1-3. To do this
we constructed a coarse version of X defined as
X∗(X) = p if qp−0.1 < X ≤ qp, p ∈ {0.1, 0.2, ..., 1},
where qp is the 100p-percentile of the empirical distribution of X. Treating
X∗ as an ordinal variable we fitted the model
logitPr(Z = 1|X∗ = p, C) = ν + δp + ωTC.
If we assume that η(x′, C) = η(x,C) if X∗(x′) = X∗(x), then the testable
criterion in (22) translates to δp ≥ δp′ if p ≥ p′. Figure 2 displays δˆp,
p ∈ {0.1, 0.2, ..., 1}, together with the corresponding 95% confidence intervals.
There is a strong trend, which is consistent with the assumptions. There are
a few exceptions to monotonically increasing values of δp (δˆ0.3, δˆ0.5, δˆ1), which
may indicate a violation of the assumptions, but may also be explained by
sampling variability.
In a preliminary analysis, we fitted the following standard model
E(Y |Z = 1, X,Age, BMI; ξ) = ξ0 + ξ1X + ξ2Age + ξ3BMI.
We obtained ξˆ1 = −0.018, with 95% Wald confidence interval (-0.031,-0.004).
To obtain an estimate of m(x,C), using the implicit method of Section 4.2.1,
we additionally fitted the model
logitPr(Z = 1|X,Age, BMI;α) = α0 + α1X + α2Age + α3BMI. (25)
We obtained αˆ1 = 0.21. Using an identity link, g(·), we replaced ξ1 and α1 in
(23) with their estimates, ξˆ1 and αˆ1. We used the delta method to obtain 95%
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Figure 2: δˆp, p ∈ {0.1, 0.2, ..., 1}, together with 95% Wald confidence intervals.
point-wise Wald confidence limits for m(x,C; ξˆ, αˆ), for x ∈ (0, 10). Figure 3
displays the result. As predicted by the theory, lim
x→0
m(x,C; ξˆ, αˆ) = ξˆ1/αˆ1 =
−0.086, and lim
x→∞
m(x,C; ξˆ, αˆ)/x = ξˆ1 = −0.018.
We next fitted a model for m(x,C) directly, using the explicit method of
Section 4.2.2. We used an identity link, g(·) = ·, and assumed a linear main
model
m(x,Age, BMI;ψ) = ψ0 + ψ1x. (26)
We assumed the logistic model for pi(X,C) in (25), and the additional nuisance
models
E(Y |Z = 1, X = 0,Age, BMI; β) = β0 + β1Age + β2BMI, (27)
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Figure 3: m(x,C; ξˆ, αˆ) with 95% point-wise Wald confidence limits.
logitPr(X = 0|Age, BMI; γ) = γ00 + γ01Age + γ02BMI, (28)
Pr(X = x|X 6= 0,Age, BMI; γ) = τ(Age, BMI; γ)exp{−τ(Age, BMI; γ)x},
(29)
where
logτ(Age, BMI; γ) = γ10 + γ
1
1Age + γ
1
2BMI.
ψ ψ
(30)
The model for Pr(X|Age, BMI) is a mixture of a point mass in X = 0, and an
exponential decay model on the range (0,∞), which appeared to be consistent
with the data. Fitting the main and the nuisance models to the CAHRES data,
using the method proposed in Section 4.2.2 (with d(Xi, Ci) = d˜
opt(Xi, Ci)),
gave the following estimate of ψ with 95% Wald confidence interval:
0ˆ = −0.197(−0.483, 0.088), 1ˆ = 0.015(−0.048, 0.079). (31)
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ψψ
ψ ψ
Comparing the implicit model and the explicit model shows that 0ˆ <
ξˆ1/αˆ1. Thus, the explicit model indicates a larger non-HRT-dependent dif-
ference in prognosis between women with different tumor subtypes, than the
implicit model. The explicit model, however, indicates a positive x-gradient in
m(x,C) ( 1ˆ > 0), whereas the implicit model indicates a negative x-gradient
(ξˆ1 < 0). The estimates obtained from the explicit model are more uncer-
tain than the estimates obtained from the implicit model. In particular, the
confidence intervals for (ψ0, ψ1) both contain 0 (no difference), whereas the
confidence intervals for (ξ1/α1, ξ1) do not contain 0. The larger uncertainty
in ( 0ˆ, 1ˆ) is the price we pay for using an approximately doubly robustness
estimation method of the parameters indexing the explicit model. To sum-
marize, our analysis indicate that women with HRT-induced tumors have a
better prognosis than women with non-HRT-induced tumors. It is not clear,
however, whether this discrepancy becomes more or less attenuated at higher
levels of HRT.
6 Simulation study
The modified explicit estimation method described in Section 4.2.2 relies heav-
ily on the rare disease assumption, A5. To investigate the sensitivity to this as-
sumption, we performed a small simulation study. We let C consist of two com-
ponents, following the joint empirical distribution of age and BMI for the con-
trols in the CAHRES study. We let Pr(X|C) follow the model in (28) and (29),
and Pr(Z|X,C) follow the model in (25). We let Pr(Y |Z = 1, X, C) follow a
normal distribution with standard deviation equal to 0.1. E(Y |Z = 1, X, C)
was defined implicitly as follows. We let m(x,C) and E(Y |Z = 1, X = 0, C)
follow the models in (26) and (27), respectively. Assuming that A1-A4 holds,
we used the relation in (4) to translate the models for m(x,C), Pr(Z|X,C),
and E(Y |Z = 1, X = 0, C) into a model for E(Y |Z = 1, X, C). For this
purpose, we used an identity link, g(·) = ·. The value of (α, β, γ, ψ) was set
to the corresponding ML-estimate from the CAHRES data, with exception
for α0 as described below. To simulate deviations from A5, we calculated the
values for α0 yielding a marginal disease prevalence, Pr(Z = 1), of 0.01, 0.05,
and 0.1, respectively. For each value of α0, 1000 samples, each with n1 = 1000
cases and n0 = 3000 controls, were drawn from the joint model. For each
sample, we applied the estimation procedure described in Section 4.2.2 (with
d(Xi, Ci) = d˜
opt(Xi, Ci)), fitting the models (26)-(30) to the data. Table 6A
displays the mean (over the 1000 samples) point estimate, mean standard error
(as calculated from the sandwhich formula), and the coverage probability of the
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ψcorresponding 95% Wald confidence interval, for Pr(Z = 1) ∈ {0.01, 0.05, 0.1}.
We observe that the method works well for Pr(Z = 1) = 0.01 (low bias and
coverage probability close to the nominal level). When the disease prevalence
increases, the performance decreases.
Theory states that ˆ is approximately consistent when either d(Xi, Ci) =
d˜opt(Xi, Ci), so that E{d(Xi, Ci)|Zi = 1, Ci} ≈ 0, or q(Ci) = qopt(Ci). To
verify this property we repeated the simulation procedure described above
with d(Xi, Ci) = G˜i and q(Ci) = q
opt(Ci). For this choice, E{d(Xi, Ci)|Zi =
1, Ci} 6= 0. We then repeated the procedure with d(Xi, Ci) =
ψ
ψ
d˜opt(Xi, Ci) and
q(Ci) = 0 6= qopt(Ci). The results are displayed in Table 6B and 6C, respec-
tively. We observe that the method works well even though E{d(Xi, Ci)|Zi =
1, Ci} 6= 0; the results in Table 6B are similar to those in Table 6A. When
q(Ci) = 0, however, the performance decreases dramatically. In particular, 0ˆ
is biased upwards and 1ˆ is biased downwards. Since the method does not
work well even at the lowest level of prevalence, we did not carry out the sim-
ulation for higher levels. Additional simulations showed, that when q(Ci) = 0
and d(Xi, Ci) = d˜
opt(Xi, Ci) the method does only perform acceptably when
the sample size is very large. Table 6D shows the result for n1 = n0 = 10000.
7 Discussion
In this paper we have used the framework of principal stratification to assess
the difference in prognosis between women with cancers caused by HRT and
women with cancers caused by other factors. We have proposed two estimation
methods for the parameters indexing a model for this difference in prognosis.
One possible extension of our approach would be to include information
on relevant tumor characteristics, such as estrogen receptor (ER) status (i.e.
to define Z/cancer more finely) in order to better identify the HRT-induced
and non-HRT-induced subtypes. An association between HRT and prognosis
is likely to be, in part, but not completely, explained by measurable tumor
characteristics. Estrogen usage is, for example, associated with the hormone
receptor status of primary breast cancer (Collins et al, 2005; Lower et al, 1999)
- breast cancers in HRT users are significantly more likely to be estrogen
receptor (ER) positive than they are in non-users. Moreover, ER-positive
breast cancer is known to have a significantly better prognosis than its ER-
negative counterpart (in part due to the fact that ER-positive cancers respond
to anti-estrogen therapies). Although extending our approach to incorporate
ER status might lead to improvements in parameter estimation efficiency, even
without such an extension, the principal stratification approach described in
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0 (= -0.197) 1 (= 0.011)
ψPr(Z = 1) mean( 0ˆ) mean(se) cp ψmean( 1ˆ) se cp
A
0.01 -0.194 0.043 0.943 0.011 0.006 0.945
0.05 -0.189 0.044 0.937 0.010 0.007 0.951
0.1 -0.178 0.045 0.893 0.010 0.007 0.933
B
0.01 -0.196 0.044 0.951 0.011 0.007 0.956
0.05 -0.192 0.045 0.915 0.011 0.007 0.932
0.1 -0.175 0.045 0.889 0.010 0.007 0.917
C
0.01 -0.141 0.379 0.956 -0.003 0.070 0.952
D
0.01 -0.180 0.136 0.964 0.008 0.026 0.961
Table 6: Mean estimate, mean standard error (se), and coverage probability
(cp) of the corresponding 95% Wald confidence interval. A: n1 = 1000, n0 =
3000, d(Xi, Ci) = d˜
opt(Xi, Ci), q(Ci) = q
opt(Ci); B: n1 = 1000, n0 = 3000,
d(Xi, Ci) = G˜i, q(Ci) = q
opt(Ci); C: n1 = 1000, n0 = 3000, d(Xi, Ci) =
d˜opt(Xi, Ci), q(Ci) = 0; D: n1 = n0 = 10000, d(Xi, Ci) = d˜
opt(Xi, Ci), q(Ci) = 0
this article, for describing the HRT-prognosis association is still interesting,
essentially because there is not a 1:1 mapping of ER status and hormone/non-
hormone induced cancer. Moreover, it is not immediately obvious how to
extend the semi-parametric approach described herein, in these terms.
The approach has other possible uses. Consider for example the new vac-
cines against human papillomavirus (HPV). It is well established that HPV
is a necessary (but not sufficient) cause of cervical cancer (Walboomers et al,
1999). Thus, a vaccination against HPV may also prevent cervical cancer.
Some women, however, may get infected even though they are vaccinated (we
call them ‘doomed’). For ethiological reasons we may want to compare the
prognosis in cervical cancer for these women against the prognosis for those
who get infected only if they are not vaccinated (we call them ‘sensitive’). Our
method can be used to estimate the mean difference in prognosis for these types
of women, provided that the vaccine has no effect on the cancer prognosis for
the doomed. Given that the vaccine is target against HPV and not cervical
cancer per se, this assumption may be reasonable to make.
Our work is closely related to a number of recent publications on post-
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treatment selection bias (Zhang and Rubin, 2003; Gilbert et al, 2003; Jemiai,
2005; Jemiai et al, 2007; Shepherd et al, 2006, 2007; Sjolander et al, 2009).
These papers have focused on a scenario where each study participant receives
one level of a binary treatment. After treatment, some subjects experience a
particular event and, for this subgroup, an outcome is measured. The estimand
of interest is the treatment effect for those subjects who would experience the
event, regardless of whether they are treated or not. Using the terminology
from Section 1, we may call those subjects ‘doomed’. Since the ‘doomed’ are
only observable in the untreated arm (see Section 1), this principal stratum
effect is not in general identified. Zhang and Rubin (2003) derived bounds for
the effect, and Jemiai (2005) proposed a sensitivity analysis. In this sensitivity
analysis, the difference in outcome distributions for doomed and harmed is
quantified in a selection bias parameter. This parameter is varied over a range
of plausible values, and each value is mapped into one value for the principal
stratum effect. The connection to our work is clear if we think about the
treatment as HRT, the post-treatment event as ‘cancer’, and the outcome as
‘prognosis’. Our work is different, however, in that we a priori assume the
treatment effect for the doomed to be zero (A4). Our scientific interest lies
instead in the selection bias parameter, m(x,C), which, under the assumption
of no effect for the doomed (A4), is identified.
A Proof of (1) and (3).
pi(x,C) = Pr{Z(x) = 1|X = x,C}
= Pr(R ≤ x|X = x,C)
= Pr(R ≤ x|C).
The first equality follows from A1, the second from A2, and the third from
A3.
Pr(Y |Z = 1, X = x,C)
= Pr{Y (x)|Z(x) = 1, X = x,C}
= Pr{Y (x)|R ≤ x,X = x,C}
= Pr{Y (x)|R ≤ x,C}
= Pr{Y (x)|R = 0, C}pi(0, C)
pi(x,C)
+ Pr{Y (x)|0 < R ≤ x,C}
{
1− pi(0, C)
pi(x,C)
}
(32)
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The first equality follows from A1, the second from A2, the third from A3,
and the fourth from Bayes rule together with (1).
B Proof that A1-A4 do not imply any other
restrictions on Pr(Y, Z,X,C) than (2) and
(5).
The proof follows the structure of Appendix A in Jemiai et al (2007). Consider
an arbitrary joint distribution Pr∗(Y, Z,X,C) satisfying the restrictions in (2)
and (5). To prove that (2) and (5) are the only restrictions implied by A1-
A4, we must be able to construct a joint distribution Pr(Y (·), Z(·), Y, Z,X,C)
which satisfies A1-A4 and marginalizes to Pr∗(Y, Z,X,C). We do this in the
absence of covariates C since the construction can be repeated within levels
of C. We construct the candidate distribution as follows:
1. Pr(Y, Z,X) ≡ Pr∗(Y, Z,X).
2. Given (Y, Z,X = x), {Y (x), Z(x)} ≡ (Y, Z).
3. We impose Z(x) ≥ Z(x′) if x ≥ x′, and define R as the minimum level
x for which Z(x) = 1.
4. From step 2 and step 3 it follows that
Pr(R ≤ r|Y = y, Z = z,X = x) =
{
0 if z = 0 and r ≤ x
1 if z = 1 and r > x
5.
Pr(R ≤ r|Y = y, Z = z,X = x)
≡
{
a(r,x)
a(∞,x) if z = 0 and r > x
b(y, x) + a(r,0)
a(x,0)
{1− b(y, x)} if z = 1 and r ≤ x
where
a(r, x) ≡
{
Pr∗(Z = 1|X = r)− Pr∗(Z = 1|X = x) if r ∈ [0,∞)
1− Pr∗(Z = 1|X = x) if r =∞
and
b(y, x) ≡ Pr
∗(Y = y, Z = 1|X = 0)
Pr∗(Y = y, Z = 1|X = x) .
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The cumulative distribution defined in this manner is valid (i.e. mono-
tonically increasing with r, and attaining 1 at r = ∞) due to (2) and
(5).
6. Given R = 0, Y (x) ≡ Y (x′), ∀x, x′.
7. From step 2 and 6 it follows that
Pr{Y (x′) = y′|R = r, Y = y, Z,X = x}
=
{
1 if (x′ = x or r = 0) and y′ = y
0 if (x′ = x or r = 0) and y′ 6= y
8.
Pr{Y (x′) = y′|R = r, Y = y, Z,X = x} ≡ Pr{Y (x′) = y′|R = r,X = x′}
if x′ 6= x and r > 0. (33)
Note that the right-hand-side of (33) is defined implicitly by step 1, 4,
5, and 7.
Let Y−(x,x′)(·) denote the function Y (·), except the points Y (x) and Y (x′). Step
1 through 8 defines Pr(R, Y, Z,X), Pr{Y (·)|R = 0, Y, Z,X}, and Pr{Y (x′)|R =
r, Y, Z,X = x}, for all x, x′ and r > 0. We finally allow Pr{Y−(x,x′)(·)|Y (x′), R =
r, Y, Z,X = x} to be any proper distribution for all x, x′ and r > 0. That
the distribution Pr(Y (·), Z(·), Y, Z,X,C) marginalizes to Pr∗(Y, Z,X) follows
from step 1. That A1 is satisfied follows from step 2. That A2 is satisfied fol-
lows from step 3. That A4 is satisfied follows from step 6. It remains to show
that A3 is satisfied. We first show that R qX. We have that
Pr(R ≤ r|X = x) (34)
=
∫
y,z
Pr(R ≤ r|Y = y, Z = z,X = x)Pr(Y = y, Z = z|X = x)dydz
=
∫
y
I(r ≤ x)× 0× Pr∗(Y = y, Z = 0|X = x)dy
+
∫
y
I(r > x)
a(r, x)
a(∞, x)Pr
∗(Y = y, Z = 0|X = x)dy
+
∫
y
I(r ≤ x)
[
b(y, x) +
a(r, 0)
a(x, 0)
{1− b(y, x)}
]
Pr∗(Y = y, Z = 1|X = x)dy
+
∫
y
I(r > x)× 1× Pr∗(Y = y, Z = 1|X = x)dy
= Pr∗(Z = 1|X = r). (35)
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Hence, R qX.
We now show that Y (x) q X|R. We first consider the case when R = 0.
In this case we have that
Pr{Y (x′) = y′|R = 0, X = x}
=
∫
y,z
[
Pr{Y (x′) = y′|R = 0, Y = y, Z = z,X = x}
× Pr(R = 0, Y = y, Z = z|X = x)dydz
]
/Pr(R = 0|X = x)
=
{
Pr(R = 0|Y = y′, Z = 0, X = x)Pr(Y = y′, Z = 0|X = x)
+ Pr(R = 0|Y = y′, Z = 1, X = x)Pr(Y = y′, Z = 1|X = x)
}
/Pr(R = 0|X = x)
=
0× Pr∗(Y = y′, Z = 0|X = x) + b(y′, x)Pr∗(Y = y′, Z = 1|X = x)
Pr(R = 0|X = x)
= Pr∗{Y = y′|Z = 1, X = 0},
where the last equality follows, since from (34), Pr(R = 0|X = x) = Pr∗(Z =
1|X = 0). Hence, Y (x) qX|R = 0. When R > 0 it follows immediately from
step 8 that Y (x)q (Y, Z,X)|R. Hence, Y (x)qX|R = r, ∀r, which concludes
the proof.
C Proof that the estimating equation in (13)
is unbiased and doubly robust.
When g(·) is the identity link and H(ψ) is defined as in (11), we have that
E(Y |Z = 1, X = 0, C) = E(Y |Z = 1, X, C)−m(X,C;ψ)
{
1− pi(0, C)
pi(X,C)
}
= E{H(ψ)|Z = 1, X, C}, (36)
where the first equality follows from (4), and the second from the definition of
H(ψ). When g(·) is the log link, equality between E(Y |Z = 1, X = 0, C = c)
and E{H(ψ)|Z = 1, X, C} holds when H(ψ) is defined as in (12). Since
E(Y |Z = 1, X = 0, C) is not a function of x we have that
E{H(ψ)|Z = 1, X, C} = E{H(ψ)|Z = 1, C}. (37)
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An immediate consequence is that
E{d(X,C)H(ψ)|Z = 1, C} = E[E{d(X,C)H(ψ)|Z = 1, X, C}|Z = 1, C]
= E{d(X,C)|Z = 1, C}E{H(ψ)|Z = 1, C},
(38)
where the second equality follows from (37). Now, rewrite
E[d(X,C)Z{H(ψ)− q(C)}]
= E
[
E[d(X,C){H(ψ)− q(C)}|Z = 1, C]Pr(Z = 1|C)
]
= E
[
E{d(X,C)|Z = 1, C}[E{H(ψ)|Z = 1, C} − q(C)]Pr(Z = 1|C)
]
,
(39)
where the second equality follows from (38). The right handside of (39) equals
0 when either E{d(X,C)|Z = 1, C} = 0 or q(C) = E{H(ψ)|Z = 1, C}.
Combining (36) with (37) shows that E{H(ψ)|Z = 1, C} = E(Y |Z = 1, X =
0, C). Finally, since the estimation procedure that we propose for d(X,C) does
not rely on the model for q(C) and vice versa (see Section 3.2.2), the doubly
robustness follows.
D Derivation of the efficient index functions
for the estimating equation in (13).
Let M be the model defined by A2-A4, models (9) and (14). Then it follows
from Appendix B that, under assumption A1, the observed data laws allowed
by model M are those satisfying
E(Z|X,C) = pi(X,C;α)
E{H(ψ, α)|Z = 1, X, C} = E{H(ψ, α)|Z = 1, C} (40)
where H(ψ, α) is defined like H(ψ) but with pi(0, C) and pi(X,C) substi-
tuted with pi(X,C;α) and pi(0, C;α), respectively. The model can therefore
be parameterized with the known function pi(X,C;α), the unknown finite-
dimensional parameters ψ and α, and infinite-dimensional parameters η1 and
η2 indexing f(Y |Z,X,C), which satisfies (40), and f(X,C), respectively. Specif-
ically, the likelihood of the observed data can be written as
f(Y |Z,X,C; η1, ψ, α)f(Z|X,C;α)f(X,C; η2)
28
The International Journal of Biostatistics, Vol. 6 [2010], Iss. 1, Art. 20
DOI: 10.2202/1557-4679.1225
Brought to you by | Universiteit Gent (Universiteit Gent)
Authenticated | 172.16.1.226
Download Date | 6/11/12 4:33 PM
where the dependence of f(Y |Z,X,C) on (ψ, α) is implied by (40). The nui-
sance tangent space for this model is Λnuis = Λ1,nuis + Λ2,nuis where Λ2,nuis =
{a (X,C) : E [a (X,C)] = 0} ∩L2 (P ) is the closed linear span of all scores for
parametric submodels for the joint law of (X,C) and
Λ1,nuis = {a(H,Z,X,C) : E[a(H,Z,X,C)|Z,X,C] = 0,
E[Ha(H,Z,X,C)|Z = 1, X, C] = E[Hat(H,Z,X,C)|Z = 1, C]} ∩ L2(P )
is the closed linear span of all scores for parametric submodels for the joint
conditional law of H ≡ H(ψ, α), given (Z,X,C).
Denote σ2 (X,C) ≡ Var (H|Z = 1, X, C) . The orthocomplement to Λ2,nuis
in the Hilbert space L02 (P ) (with covariance inner product) of functions in
L2 (P ) with mean zero is Λ
⊥
2,nuis = {d(H,Z,X,C) : E [d(H,Z,X,C)|X,C] = 0}∩
L02 (P ) because the orthogonal projection of an arbitrary function e(H,Z,X,C)
in L02 (P ) onto Λ2,nuis is E {e(H,Z,X,C)|X,C}. Let d(H,Z,X,C) be an ar-
bitrary function, and define
K (H, d) = Cov (H, d (H,Z,X,C) |Z = 1, X, C) ,
J (H, d) = K (H, d)
− E [σ−2 (X,C) |Z = 1, C]−1E [σ−2 (X,C)K (H, d) |Z = 1, C] .
The orthocomplement to Λ1,nuis in L
0
2 (P ) is then
Λ⊥1,nuis = {E[d(H,Z,X,C)|Z,X,C]
+ σ−2(X,C)J(H, d)Z[H − E(H|Z = 1, C)]} ∩ L02 (P ) ,
since the orthogonal projection of an arbitrary function e(H,Z,X,C) in L02 (P )
onto Λ1,nuis is
e(H,Z,X,C)− E [e(H,Z,X,C)|Z,X,C]
− σ−2 (X,C) J (H, e)Z [H − E(H|Z = 1, C)] .
Because Λ1,nuis and Λ2,nuis are mutually orthogonal, the orthogonal projection
of an arbitrary function e(H,Z,X,C) in L02 (P ) onto Λnuis = Λ1,nuis + Λ2,nuis
as the sum of the separate projections onto Λ1,nuis and Λ2,nuis, so that
Λ⊥nuis = {E [d(H,Z,X,C)|Z,X,C]− E [d(H,Z,X,C)|X,C]
+σ−2 (X,C) J (H, d)Z [H − E(H|Z = 1, C)]} ∩ L02 (P )
To find the efficient scores for ψ and α, note from the model formulation
that the scores Sψ for ψ and Sα for α under parametric submodels satisfy the
following restrictions
E (Sψ|Z = 1, X, C) = 0
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E (HSψ|Z = 1, X, C)
= E (HSψ|Z = 1, C) + E
(
∂H
∂ψ
|Z = 1, C
)
− E
(
∂H
∂ψ
|Z = 1, X, C
)
(41)
Sα = S
∗
α + S
∗∗
α
S∗∗α = pi(X,C;α)
−1 {1− pi(X,C;α)}−1 {Z − pi(X,C;α)} ∂pi(X,C;α)/∂α
E (HS∗α|Z = 1, X, C) = E (HS∗α|Z = 1, C) + E
(
∂H
∂α
|Z = 1, C
)
− E
(
∂H
∂α
|Z = 1, X, C
)
+ Cov(H,S∗∗α |Z = 1, C)
where S∗α ≡ ∂ log f(Y |Z,X,C; η1, ψ, α)/∂α, S∗∗α = ∂ log f(Z|X,C;α)/∂α and
Cov(H,S∗∗α |Z = 1, C) = Cov{E(H|Z = 1, C), S∗∗α |Z = 1, C}
+E{Cov(H,S∗∗α |Z = 1, X, C)} = 0
The efficient score for ψ is now obtained as the orthogonal projection of S
onto Λ⊥nuis which, from previous results, equals
σ−2 (X,C) Jeff,ψ (H, d)Z [H − E(H|Z = 1, C)]
where Jeff,ψ (H, d) is defined like J (H, d), but with K (H, d) replaced with
−E [∂H(ψ, α)/∂ψ|Z = 1, X, C]. This can be seen because Cov(H,Sψ |Z =
1, X, C) = E (HSψ|Z = 1, X, C), which is given by (41), where the first two
terms in the righthand side of (41) do not contribute to the expression for
J(H,Sψ) because they are functions of only C. Likewise, the efficient score
for α is obtained as the orthogonal projection of Sα onto Λ
⊥
nuis which, from
previous results, equals
E(Sα|Z,X,C)− E(Sα|X,C)
+ σ−2 (X,C) Jeff,α (H, d)Z [H − E(H|Z = 1, C]
= S∗∗α + σ
−2 (X,C) Jeff,α (H, d)Z [H − E(H|Z = 1, C)]
where Jeff,α (H, d) is defined like J (H, d), but with K (H, d) replaced with
−E [∂H(ψ, α)/∂α|Z = 1, X, C].
Consider now the model M∗ defined by A2-A4, (9), (14) and (19). Then
a similar development shows that the efficient scores for ψ and α are as given
above, and that the efficient score for γ equals ∂ log f(X|C; γ)/∂γ.
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E Derivation of the asymptotic variance for θˆ
under case-control sampling.
The proof follows closely the proof in Prentice and Pyke (1979). A first-order
Taylor expansion of
∑n
i=1 Ui(θˆ) = 0 about the true value θ gives
n∑
i=1
Ui(θˆ) =
n∑
i=1
Ui(θ) +
∂
∑n
i=1 Ui(θ)
∂θ
(θˆ − θ) = 0, (42)
or
n1/2(θˆ − θ) =
{
−n−1
n∑
i=1
∂Ui(θ)
∂θ
}−1
n−1/2
n∑
i=1
Ui(θ). (43)
According to the law of large numbers, n−1
∑n
i=1
∂Ui(θ)
∂θ
converges almost surely
to I. We can rewrite n−1/2∑ni=1 Ui(θ) as
n−1/2
n∑
i=1
Ui(θ)
=
∑
z∈{0,1}
(nz/n)
1/2
[
n−1/2z
n∑
i=1
I(Zi = z){Ui(θ)− µz}
]
+ n−1/2
∑
z∈{0,1}
nzµz,
where µz = E{Ui(θ)|Z = z}. The central limit theorem can be applied to the
terms in square brackets. Also, it follows from results in Prentice and Pyke
(1979), that
∑
z∈{0,1} nzµz = 0. Hence, n
−1/2∑n
i=1 Ui(θ) is asymptotically
normal with mean 0 and variance J .
F Proof that Pr(X|Z = 1, C) is variation inde-
pendent of η(X,C).
We carry out the proof in the absence of covariates, for brevity.
Define Pr(Z = z,X = x) ≡ p(z, x). The function p(z, x) is restricted by
0 ≤ p(z, x) ∀z, x, (44)
1 =
∫
p(1, x)dx+
∫
p(0, x)dx. (45)
Thus, at a given value z ∈ {0, 1}, p(z, x) is restricted by
0 ≤ p(z, x) ∀x, (46)
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∫
p(z, x)dx ≤ 1. (47)
From Bayes rule we have that
η(x) ≡ pi(x){1− pi(0)}
pi(0){1− pi(x)} =
p(1, x)p(0, 0)
p(1, 0)p(0, x)
. (48)
η(x) is restricted by
η(0) = 1, (49)
0 ≤ η(x) <∞ ∀x. (50)
Pr(X|Z = 1) is determined by the function p(1, x). Thus, Pr(X|Z = 1) and
η(X) are variation independent if p(1, X) and η(X) are variation independent.
Consider an arbitrary function p∗(1, x) satisfying (46) and (47) with z = 1,
and an arbitrary function η∗(x) satisfying (49) and (50). To prove that p(1, X)
and η(X) are variation independent we must be able to construct a full law
p(z, x) which a) marginalizes to p∗(1, z), b) is indexed by η(x) = η∗(x), c)
satisfies (44) and (45). We first define
p(1, x) ≡ p∗(1, x), (51)
η(x) ≡ η∗(x). (52)
From (48) we have that
p(0, x) =
p(0, 0)
p(1, 0)
p(1, x)η−1(x). (53)
Substituting into (45) and solving for p(0, 0) gives
p(0, 0) =
p(1, 0){1− ∫ p(1, x)dx}∫
p(1, x)η−1(x)dx
.
Substituting back into (53) gives
p(0, x) =
{
1−
∫
p(1, x)dx
}
p(1, x)η−1(x)∫
p(1, x)η−1(x)dx
. (54)
The law defined by (51), (52) and (54) satisfies a), b), and c) listed above.
Thus, p(1, X) and η(X) are variation independent, which implies that Pr(X|Z =
1) and η(X) are variation independent. In addition, we observe that the law
defined by (51), (52) and (54) is the only possible candidate for p(z, x). Thus,
as a byproduct of the proof we get that p(1, X) and η(X) together fully specify
the joint distribution p(Z,X).
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